

CM 21134 - MacCONKEY SORBITOL AGAR BASE W/RHAMNOSE

INTENDED USE

For improved differentiation of Escherichia coli O157:H7 from background flora.

PRODUCT SUMMARY AND EXPLANATION

E. coli O157:H7 is a human pathogen associated with hemorrhagic colitis that results from the action of a shiga-like toxin. MacConkey agars are selective media and recommended as differential plating media for detection and isolation of coliforms from various samples clinical, dairy, food, water, pharmaceuticals etc. Of different E. coli strains, E. coli O157:H7 which is a hemorrhagic strain does not ferment sorbitol or rhamnose. This biochemical feature aids in differentiating E. coli O157:H7 from other E. coli strains. Generally, on standard MacConkey Agar medium containing lactose, this strain cannot be differentiated from other lactose fermenting E. coli. Rhamnose is often fermented by most sorbitol negative Escherichia coli of other serogroups.

MacConkey Sorbitol Agar Base w/ Rhamnose contains two sugars as sorbitol and rhamnose. Since E. coli O157:H7 do not usually ferment sorbitol or rhamnose it appears as colourless to straw coloured colonies. While rhamnose positive and sorbitol negative appear as pink or red coloured colony and it should not be counted as presumptive Escherichia coli O157:H7.

COMPOSITION

Ingredients	Gms / Ltr
<i>Peptic Digest of Animal Tissue</i>	20.000
<i>Rhamnose</i>	5.000
<i>D-Sorbitol</i>	10.000
<i>Bile salts mixture</i>	1.500
<i>Sodium chloride</i>	5.000
<i>Neutral red</i>	0.030
<i>Crystal violet</i>	0.001
<i>Agar</i>	15.000

PRINCIPLE

MacConkeySorbitol Agar Base w/ Rhamnose contains peptic digest of animal tissue in the medium which supplies necessary nutrients to growing cells. Crystal violet and bile salts mixture present in the medium inhibits growth of gram positive bacteria. Addition of cefixime significantly reduces the number of sorbitol nonfermentors that are to be screened during the attempted isolation of E. coli O157: H7. The isolated suspected colonies of E. coli O157: H7obtained on this medium can be further confirmed using the LK13 E. coli Latex Test kit.

INSTRUCTION FOR USE

- Dissolve 56.53 grams in 1000 ml distilled water.
- Heat to boiling to dissolve the medium completely.
- Sterilize by autoclaving at 15 psi pressure (121°C) for 15 minutes.
- Cool to 45-50°C and aseptically add rehydrated contents of 2 vials of Cefixime Supplement.
- Mix well and pour into sterile Petri plates.

QUALITY CONTROL SPECIFICATIONS



Appearance of Powder	: Light yellow to pink homogeneous free flowing powder.
Appearance of prepared medium	: Purplish red coloured, clear to slightly opalescent gel forms in Petri plates.
pH (at 25°C)	: 7.1±0.2

INTERPRETATION

Cultural characteristics observed after an incubation.

<i>Microorganism</i>	<i>ATCC</i>	<i>Inoculum (CFU/ml)</i>	<i>Growth</i>	<i>Recovery</i>	<i>Colour of Colony</i>	<i>Incubation Temperature</i>	<i>Incubation Period</i>
<i>Escherichia coli</i>	25922	50-100	Good-luxuriant	≥50 %	Pink to red	35-37°C	18-24 Hours
<i>Escherichia coli</i> O157:H7	NCTC 12900	50-100	Good-luxuriant	≥50 %	Straw coloured	35-37°C	18-24 Hours
<i>Proteus mirabilis</i>	29906	≥10 ³	Inhibited	0%	-	35-37°C	18-24 Hours

PACKAGING:

In pack size of 500 gm bottles.

STORAGE

Dehydrated powder, hygroscopic in nature, store in a dry place, in tightly-sealed containers between 25-30°C and protect from direct sunlight. Under optimal conditions, the medium has a shelf life of 4 years. When the container is opened for the first time, note the time and date on the label space provided on the container. After the desired amount of medium has been taken out replace the cap tightly to protect from hydration.

Product Deterioration: Do not use if they show evidence of microbial contamination, discoloration, drying or any other signs of deterioration.

DISPOSAL

After use, prepared plates, specimen/sample containers and other contaminated materials must be sterilized before discarding.

REFERENCES

1. March and Ratnam 1986. J. Clin Microbiol, 23:869.
2. Centre for Diseases control. 1991. Morbid. Mortal. Weekly Rep 40:265.
3. Bopp, Brenner, Wells and Stockbine. 1999. In Murray, Baron, Tenover and Tenover (ed.) Manual of Clinical Microbiology, 7th ed. American Society for Microbiology, Washington, DC.
4. Sanderson, Gay, Hancock, Gay, Fox and Besser, 1955. J Clin Microbiol. 33: 2616.
5. Chapman, P.A., Siddons, C.A., Zadik, P.M and Jewes L. (1991). J Med Microbiol 35: 155.

